COMPASS Pathways Granted Patent Covering Use of Its Psilocybin Formulation in Addressing Treatment-resistant Depression

COMPASS Pathways

2020/1/14 10:12

COMPASS Pathways Granted Patent Covering Use of Its Psilocybin Formulation in Addressing Treatment-resistant Depression

PR82493

LONDON, January 13, 2020 /PRNewswire=KYODO JBN/--

COMPASS Pathways, a mental health care company, announced today that it has been granted

US Patent No 10,519,175, relating to methods of treating drug-resistant depression with

a psilocybin formulation, by the US Patent and Trademark Office. The patent covers the use

of COMPASS's synthesised investigational psilocybin formulation, COMP360, in a psilocybin

therapy protocol for patients with treatment-resistant depression. Psilocybin is an active

ingredient in so-called 'magic mushrooms'.

Last month, COMPASS reported [https://www.prnewswire.com/news-releases/compass-pathways-and-kings-college-london-announce-results-from-psilocybin-study-in-healthy-volunteers-300973347.html ] that COMP360 was well tolerated when administered to healthy

adult volunteers with support from specially trained therapists in a randomised

placebo-controlled trial. COMPASS is currently running a phase IIb clinical trial

[https://clinicaltrials.gov/ct2/show/NCT03775200 ] of COMP360 in treatment-resistant

depression. This trial is recruiting 216 patients from across Europe and North America

who suffer with depression that hasn't responded to established medications, and will be

the largest clinical trial of a psilocybin formulation to date. In 2018, COMPASS received FDA

"Breakthrough Therapy" designation [https://www.prnewswire.com/news-releases/compass-pathways-receives-fda-breakthrough-therapy-designation-for-psilocybin-therapy-for-treatment-resistant-depression-834088100.html ] for its programme of psilocybin therapy for treatment-resistant depression.

George Goldsmith, CEO and Co-founder, COMPASS Pathways, said, "Too many people are

suffering with treatment resistant depression. We are committed to developing innovations,

such as psilocybin therapy, to address this rapidly growing problem. Patents help ensure

sustainable funding to conduct the highest quality clinical research to bring the best new

therapies to patients who urgently need them. If this research demonstrates psilocybin

therapy is a safe and effective option for patients, we will price it responsibly with the goal

of making it as affordable and accessible as possible."

About COMPASS Pathways

COMPASS Pathways is a mental health care company dedicated to accelerating

patient access to evidence-based innovation in mental health. We are developing

psilocybin therapy through a late-stage clinical trial in Europe and North America

for patients with treatment-resistant depression. COMP360 is an investigational

psilocybin formulation developed and produced by COMPASS Pathways.

www.compasspathways.com

Logo - https://mma.prnewswire.com/media/733890/COMPASS_Pathways_Logo.jpg

Enquiries:

Tracy Cheung, tracy@compasspathways.com, +44 7966 309024

Amy Lawrence, amy@compasspathways.com, +44 7813 777919

SOURCE: COMPASS Pathways

本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。

このプレスリリースには、報道機関向けの情報があります。

プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。

プレスリリース受信に関するご案内

SNSでも最新のプレスリリース情報をいち早く配信中